Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metrics Offers Proprietary Pellet Forms for Advanced Drug Release

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Unique pellet formulations help support therapeutic effectiveness of active pharmaceutical ingredients.

Metrics Inc. now offers proprietary pellet technologies enabling controlled release of active pharmaceutical ingredients (API).

The company’s advanced drug delivery technology supports the therapeutic effectiveness of API by tailoring drug release to the specific application and desired end point.

For a patient, the potential benefits of this technology are fewer doses and fewer side effects, notably gastrointestinal symptoms such as nausea – thereby increasing patient compliance. Metrics’ ability to offer these technologies results from the company’s recent acquisition by Mayne Pharma Group Limited.

Mayne Pharma has successfully applied pellet technology to a number of proprietary pharmaceuticals with modified release profiles, including Eryc™ (delayed release erythromycin), Doryx™ (delayed release doxycycline), Kadian™ (extended release morphine), Astrix™ (delayed release low-dose aspirin) and pulsed release diltiazem. The combined sales of these proprietary drugs exceed $500 million annually.

“At the end of the day, pharmaceutical science is all about making drugs as effective and tolerable as possible so that patients can experience both better health and a better quality of life when taking necessary medications,” said Dr. Brad Gold, vice president of pharmaceutical development at Metrics. “It’s exciting to offer pellet formulation to our clients – and to the patients they seek to help.”

Advanced pellet formulations can be developed for:

•    Sustained release, delivering steady levels of API 12 to 24 hours after administration.
•    Pulsed release, delivering pulses of API 12 to 24 hours after administration.
•    Modified release, delivering API in any modification from immediate release, and
•    Delayed release, allowing API to pass through the stomach undigested so that it can be absorbed in the small intestine.

Metrics and Mayne offer two technologies for formulations:

•    The first, called extrusion granulation, granulates API with excipients, which is extruded to form a core then coated by polymers. This process allows potencies up to 90 percent.
•    The second, called spheronization, applies drug particles to a “seed” core – typically sugar – with the aid of a binder. The core is coated with a polymer. This process provides a very tight size distribution of pellets. Potencies up to 60 percent are possible.

Metrics Inc. is a full-service global pharmaceutical development and manufacturing organization serving clients worldwide. We deliver proven scientific and operational excellence for solid oral dosage forms.

The company’s areas of expertise include quality pharmaceutical formulation development; first-time-inman (FTIM) formulations; clinical material manufacturing (CTM) for Phase I, II and III trials; and analytical method development and validation services leading to commercial scale manufacturing.

Metrics’ technical capabilities include highly potent, cytotoxic and unstable compounds; Schedule II-V controlled substances; and products with poor bioequivalence – for which we offer an impressive proprietary portfolio of advanced delivery methods.

Our work supports investigational new drug (IND), new drug (NDA) and abbreviated new drug (ANDA) submissions made to worldwide regulatory agencies on behalf of clients ranging from internationally renowned corporations to small virtual companies.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!